694 NDMM patients, one message: hyperdiploid myeloma is not one risk group. A modal count >49 and trisomy 3 predicted longer OS and PFS, and the ASCT OS benefit was limited to low-risk HRD with >49 chromosomes (BJH).
PMID 42760862
#mmsm#myeloma#MedTwitter#MedEd
Genomic instability: A potential predictor of immunotherapy resistance
An important translational study linking genomic instability with treatment outcomes.
DLP+ single-cell WGS analyzed 5,454 cells from 14 MM samples, with validation in 96 additional samples.
The investigators identified two biological groups:
• Genomically stable disease.
• Genomically unstable disease, characterized by subclonal diversification, whole-genome doubling, convergent evolution, telomeric erosion and complex structural variants.
Clinical observations were striking:
• All 4 genomically unstable NDMM patients failed to achieve MRD negativity and progressed within 30 months.
• None of 7 genomically stable patients progressed after 7 years.
• In a small anti-BCMA bispecific validation cohort, genomic instability was associated with rapid progression.
Could genomic instability become a clinically relevant biomarker of immunotherapy resistance?
onlineprogram.hematology.org…
13/17 #ASH26#mmsm
Fat pad beats marrow for confirming AL amyloidosis: pooled sensitivity 77% vs 55% across 31 studies (Blood Advances meta-analysis). Both together reached 89% in a Mayo series. A simple aspirate can spare many an organ biopsy.
PMID 42696041
#mmsm#myeloma#MedTwitter#MedEd
Next week, Tempus will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society Annual Meeting (November 18–21).
In rare diseases like sarcoma, small patient populations have historically created barriers to research. By leveraging our multimodal library, which includes real-world data from more than 45,000 patients across 615 rare and ultra-rare cancer types, our team is uncovering novel insights into rare mesenchymal tumors to advance precision oncology.
Read the full announcement to learn more: tempus.co/4zKUQww#CTOS2026
Our CEO and Founder @lefkofsky recently joined @MTSlive to discuss the evolving role of AI in clinical care as patients increasingly consult #GenAI tools with their own health data.
Over the next 3 to 5 years, healthcare systems must equip physicians with the same caliber of advanced, intelligent technology to support clinical decision-making.
Sonrotoclax: Targeting BCL2 in t(11;14) myeloma
BCL2 remains an attractive therapeutic vulnerability in t(11;14) MM.
Phase Ib/II sonrotoclax + daratumumab + dexamethasone (SDd) study (n=72).
Median 3 prior lines; 56% triple-class exposed and 22% triple-class refractory.
Among 70 response-evaluable patients:
• ORR: 87%.
• ≥VGPR: 59%.
• ≥CR: 23%.
• Median time to response: 1 month.
• 12-month PFS: 69%.
Grade 3/4 neutropenia: 28%.
Grade 3/4 infections: 21%.
No treatment-related discontinuations due to sonrotoclax.
A compelling targeted strategy for molecularly selected MM.
onlineprogram.hematology.org…
9/17 #ASH26#mmsm
Most of us wait for relapse after CAR-T. The Penn group is asking why wait.
Adam Cohen presented the updated STEM trial at #IMS26: cevostamab consolidation starting 10 to 12 weeks after commercial cilta-cel or ide-cel. 27 pts, 74% triple-class refractory, 41% with 2 or more high-risk features, 19% with EMD.
At 1 yr post CAR-T: 24 of 27 in sCR, 25 MRD-neg at 10^-5, 23 at 10^-6. Cohen calls it 89% sustained MRD-neg CR, with "promising" 2-yr PFS.
- The logic is good. FcRH5 is a different target, so a BCMA-escape clone has less room to hide, and you're hitting the disease when burden is at its lowest
- The cost is cytopenias stacked on post-CAR-T cytopenias. Neutropenia 78% (48% G3/4), lymphopenia 67% G3/4. Seven pts held doses, six dropped to 90 mg
- In the 2025 interim, both step-up doses came with a 48-hr admission. That's a site capacity issue as much as a toxicity one
The bigger challenge is translational. Single arm, 27 pts, and the comparator in our heads is cilta-cel alone, where a lot of pts are already MRD-neg at 1 yr. Without a control we can't seperate what cevo added from what the CAR-T was doing anyway. Good news: the team says a multicenter randomized phase 2 is in development, which is excatly the right next step.
If we can pick out the pts heading for early relapse and consolidate only them, this gets a lot easier to justify.
#CARTcell#Myeloma#IMS26
Same myeloma, different postcode. In 4,405 Australians, low-SES patients were less likely to get ASCT and had median OS of 78.5 vs 86.7-92.5 mo, inside universal healthcare. Access is part of the treatment.
PMID 43009481
#mmsm#myeloma#MedTwitter#MedEd